The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the 340B Drug Pricing Program and the legal battle to stop it.

Too many hospitals take advantage of 340B, intended to make medications affordable for low-income patients. A New York ...

Hospital groups raise issues with 340B rebate pilot program citing cash flow, administrative costs, and unclear rebate denials risks.

Ten medications accounted for nearly one-third of 340B program-covered outpatient drugs in 2024, according to a Dec. 11 report.  The Health Resources and Services Administration, an HHS agency, ...

The 340B Drug Pricing Program was meant to help low-income patients, writes Rick Dowlearn, but it’s being used by hospitals ...

Michigan hospitals are systematically exploiting a program for low-income patients, according to a new report.

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

The past year has seen a great deal of controversy surrounding the 340B Drug Pricing Program, in which drug manufacturers make prescription drugs available to safety net healthcare providers at deeply ...

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

A major consumer advocacy organization began consistently criticizing foes of pharmaceutical manufacturers after the industry’s top trade association directed large donations its way, a Washington ...